KALVISTA PHARMACEUTICALS INC KALV

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $9.00. Options: 4 managers hold calls ($739.8k notional), 2 hold puts ($958.5k).

Trends to Q2 2023

Options at notional value: the value of the shares the contracts control, as filers report them, not what the options cost. Not included in the holders, shares or buying above.

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

Fell to 5% or below in the last year: TANG CAPITAL MANAGEMENT LLC (0.0%, 2026-08-14), GLAZER CAPITAL, LLC (4.8%, 2026-06-10), Frazier Life Sciences Public Fund, L.P. (2.3%, 2026-05-21), Point72 Asset Management, L.P. (4.2%, 2026-05-15), MILLENNIUM MANAGEMENT LLC (3.7%, 2026-05-01), Vestal Point Capital, LP (1.5%, 2025-11-14)

Holders, Q2 2023